Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

8 treatments under study, led by Ban Xia Xie Xin Decoction And Bismuth Quadruplicate Group

Related Conditions

Often studied with 7 related conditions

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 5 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

4Total
Phase 1 (1)
Phase 1/2 (1)
Phase 4 (2)

Trial Status

Completed3
Unknown2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 3 completed trials

Clinical Trials (5)

Showing 5 of 5 trials
NCT06823791Phase 1/2Completed

Furazolidone Quadruple Regimen Eradicate H. Pylori Infection

NCT05586464Phase 1Unknown

Eradication of Helicobacter Pylori With Bismuth Agent Quadruple and Traditional Chinese Medicine

NCT00596401Completed

The Preventive Effect of Helicobacter Pylori Eradication on the Development of Gastric Cancer

NCT04618159Phase 4CompletedPrimary

Does Helipyl Eradicate

NCT02934048Phase 4Unknown

Optimal Duration of Antimicrobial Susceptibility Test (AST) Guided Rescue Therapy for Helicobacter Pylori Infection

Showing all 5 trials

Research Network

Common Treatments

  • Ban Xia Xie Xin Decoction And Bismuth Quadruplicate Group1
  • Furazolidone1
  • Bismuth Quadruplicate Group1
  • 7day Triple Regimen Guided By Ast1
  • Lactobacillus Reuteri Dsmz 176481

Active Sponsors

  • Liaocheng People's Hospital2
  • Showa Inan General Hospital1
  • Universitair Ziekenhuis Brussel1
  • Shandong University1

Top Investigators

Related Conditions

  • Helicobacter Pylori2
  • Helicobacter Pylori Infection2
  • Gastric Cancer1
  • Medical Care Cost1
  • Traditional Chinese Medicine1

Activity Timeline